Literature DB >> 21436081

Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment.

Gunnar Juliusson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436081     DOI: 10.1182/blood-2010-11-321737

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  23 in total

Review 1.  The artful management of older patients with acute myeloid leukemia.

Authors:  Jay Yang; Charles A Schiffer
Journal:  Expert Rev Hematol       Date:  2016-03-02       Impact factor: 2.929

2.  Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.

Authors:  Stefan Faderl; Farhad Ravandi; Xuelin Huang; Xuemei Wang; Elias Jabbour; Guillermo Garcia-Manero; Tapan Kadia; Alessandra Ferrajoli; Marina Konopleva; Gautam Borthakur; Jan Burger; Jennie Feliu; Hagop M Kantarjian
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

Review 3.  Elderly acute myeloid leukemia: assessing risk.

Authors:  Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

4.  Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.

Authors:  Koichi Takahashi; Hagop Kantarjian; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Courtney DiNardo; Elias Jabbour; Sherry Pierce; Zeev Estrov; Marina Konopleva; Michael Andreeff; Farhad Ravandi; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-11-24

5.  Acute myeloid leukemia in the real world: why population-based registries are needed.

Authors:  Gunnar Juliusson; Vladimir Lazarevic; Ann-Sofi Hörstedt; Oskar Hagberg; Martin Höglund
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

6.  Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.

Authors:  Wolfgang R Sperr; Susanne Herndlhofer; Karoline Gleixner; Michael Girschikofsky; Ansgar Weltermann; Sigrid Machherndl-Spandl; Thamer Sliwa; Rainer Poehnl; Veronika Buxhofer-Ausch; Karin Strecker; Gregor Hoermann; Paul Knoebl; Ulrich Jaeger; Klaus Geissler; Michael Kundi; Peter Valent
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

7.  Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.

Authors:  Heidi D Klepin; Janet A Tooze; Timothy S Pardee; Leslie R Ellis; Dmitriy Berenzon; Shannon L Mihalko; Suzanne C Danhauer; Arati V Rao; Tanya M Wildes; Jeff D Williamson; Bayard L Powell; Stephen B Kritchevsky
Journal:  J Am Geriatr Soc       Date:  2016-09-14       Impact factor: 5.562

8.  Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study.

Authors:  L S G Østgård; J M Nørgaard; H Sengeløv; M Severinsen; L S Friis; C W Marcher; I H Dufva; M Nørgaard
Journal:  Leukemia       Date:  2014-08-05       Impact factor: 11.528

Review 9.  Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.

Authors:  Heidi D Klepin
Journal:  Clin Geriatr Med       Date:  2016-02       Impact factor: 3.076

Review 10.  Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.

Authors:  Heidi D Klepin
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.